Page last updated: 2024-11-10
phthioic acid
Description
phthioic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3,13,19-trimethyltricosanoic acid : A methyl-branched fatty acid that is tricosanoic acid substituted by a methyl group at positions 3, 13 and 19. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 5282606 |
| CHEBI ID | 188172 |
| SCHEMBL ID | 5858405 |
| MeSH ID | M0058673 |
Synonyms (7)
| Synonym |
|---|
| 3,13,19-trimethyl-tricosanoic acid |
| LMFA01020022 , |
| phthioic acid |
| CHEBI:188172 |
| 3,13,19-trimethyltricosanoic acid |
| SCHEMBL5858405 |
| 3,13,19-trimethyltricosansaure |
Research Excerpts
Overview
Phthioic acid is unlikely to be a major pathogenicity determinant of Aspergillus.
Roles (2)
| Role | Description |
|---|
| Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| very long-chain fatty acid | A fatty acid which has a chain length greater than C22. Very long-chain fatty acids which have a chain length greater than C27 are also known as ultra-long-chain fatty acids. |
| fatty acid 26:0 | A saturated fatty acid containing 26 carbons and 0 double bonds. |
| methyl-branched fatty acid | Any branched-chain fatty acid containing methyl branches only. |
| branched-chain saturated fatty acid | Any saturated fatty acid with a carbon side-chain or isopropyl termination. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 70.52
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 70.52 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.45 (4.65) | | Search Engine Demand Index | 115.72 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |